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ABSTRACT
A T®G mutation at nucleotide 705 of human
b-globin intron 2 creates an aberrant 5¢ splice site
and activates a cryptic 3¢ splice site upstream. In
consequence, the pre-mRNA is spliced via aberrant
splice sites, despite the presence of the still func-
tional correct sites. Surprisingly, when IVS2-705
HeLa or K562 cells were cultured at temperatures
below 30°C, aberrant splicing was inhibited and
correct splicing was restored. Similar temperature
effects were seen for another b-globin pre-mRNA,
IVS2-745, and in a construct in which a b-globin
intron was inserted into a coding sequence of
EGFP. Temperature-induced alternative splicing
was affected by the nature of the internal aberrant
splice sites ¯anking the correct sites and by exonic
sequences. The results indicate that in the context
of thalassemic splicing mutations and possibly in
other alternatively spliced pre-mRNAs, temperature
is one of the parameters that affect splice site
selection.
INTRODUCTION
The mechanisms involved in alternative splicing of pre-
mRNAs are not completely understood, but a large body of
work suggests that selection of splice sites is determined by
the balance of many splicing factors interacting with splice
sites and/or other related sequence elements involved in
splicing (1±3). This balance is affected by, for example, the
presence or absence of gene-speci®c splicing factors,
especially well de®ned in Drosophila (4), or by differences
in relative concentration of antagonistic constitutive splicing
factors (5,6). Both gene-speci®c and constitutive splicing
factors that play a role in alternative splicing usually belong to
the SR family of polypeptides (6). Evidence shows that SR
proteins as well as other splicing factors are extensively
phosphorylated (7). Thus phosphorylation and dephos-
phorylation of splicing factors may add an additional regula-
tory layer to alternative splicing (8±11). There is also evidence
that cyclin E±cdk2 interacts with the splicing machinery
providing a link between splicing, and possibly alternative
splicing, and the cell cycle (12).
Elements of pre-mRNA that affect splice site selection
include exon splicing enhancers (13), secondary structures
(14) and the relative match of the 3¢ and 5¢ splice sites and
branch points to their respective consensus sequences (1±3).
The latter is well illustrated by the fact that mutations within
natural splice sites lead to activation of cryptic sites or to
skipping of exons bordered by the affected splice sites, a
phenomenon frequently seen in splicing mutations causing
genetic diseases (15). Experimental mutations that increase
the match of a splice site or a branch point to their respective
consensus sequence shift the splicing pattern and lead to
inclusion of an otherwise ignored exon (16,17). It seems likely
that these mutations either decrease or increase the af®nity of
the affected sequences for the appropriate splicing factors. The
multiple mechanisms involved in splice site selection suggest
that a dynamic network of interacting components determines
the structure and function of spliceosomes and that spliceo-
somes assembled on different splice sites may not be identical.
One can then hypothesize that changes in the physiology of the
cell might variably affect splicing of different messages,
especially those that are alternatively spliced.
We have tested this hypothesis using thalassemic mutations
IVS2-654, IVS2-705 and IVS2-745 in intron 2 of the human
b-globin gene (18) as a clinically relevant model for studies of
the mechanisms involved in pre-mRNA splicing and splice
site selection. The three mutations create aberrant 5¢ splice
sites at nucleotides 652, 706 and 745 of intron 2, respectively,
and activate a common cryptic 3¢ splice site at nucleotide 579.
Splicing of mutated b-globin pre-mRNAs is shifted either
completely or partially to aberrant pathways, even though the
correct splice sites remain potentially functional. Portions of
the intron sequences between the newly activated splice sites
are recognized by the splicing machinery as exons and are
retained in the spliced mRNAs. The retained exon-like
sequences of either 73, 126 or 165 nt generate a stop codon
that prevents proper translation of the mRNA (Fig. 1) and
causes a de®ciency in b-globin leading to b-thalassemia
(18±22). The aberrant splicing patterns of mutated b-globin
pre-mRNAs can be seen not only in patients' erythroid cells
(18) but also in 3T3, HeLa and K562 cell lines that stably
express the thalassemic b-globin genes (19,23,24).
It has been shown that abnormal splicing of thalassemic
b-globin pre-mRNA can be corrected by the use of antisense
oligonucleotides and RNAs directed against the aberrant
splice sites. Antisense oligonucleotides restored correct
splicing in cell-free extracts from HeLa cells (25), in cultured
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mammalian cells expressing the mutated b-globin genes
(19,23,24), in ex vivo treated bone marrow cells from
thalassemic mice (26) and in erythroid cells from thalassemic
patients (27). Modi®cation of splicing by antisense oligo-
nucleotides was also accomplished by targeting mutant human
CFTR (28) and murine dystrophin (29) pre-mRNAs and the
alternatively spliced human Bcl-x pre-mRNA (30,31). Here
we report that the shift in splicing of mutated pre-mRNA from
aberrant to correct is affected not only by antisense agents but




Cell lines were obtained by stable transfection of HeLa or
K562 erythroblastoid cells with the IVS2-654 or IVS2-705
thalassemic b-globin genes cloned under the cytomegalovirus
promoter as previously described (19,23). The IVS2-705
K562 cell line was a gift from Dr L. Gorman. HeLa cells
expressing the enhanced green ¯uorescent protein (EGFP)
coding sequence interrupted by the thalassemic IVS2-654 or
IVS2-705con b-globin intron 2 were generated as described in
Sazani et al. (32).
HeLa cell lines were grown in S-MEM supplemented with
5% fetal calf and 5% horse sera, 50 mg/ml gentamicin,
200 mg/ml kanamycin and 15 mM HEPES buffer (pH 7.3).
IVS2-705 K562 cells were grown in Dulbecco's modi®ed
Eagle's medium, 10% ®ltered Colorado calf serum, 100 U/ml
penicillin, 100 mg/ml streptomycin and 15 mM HEPES buffer
(pH 7.3). Cells were maintained at 37°C and 5% CO2.
Temperature treatment
For all experiments, cells were plated in 25 ml ¯asks at 2.5 3
105 cells/2.5 ml medium per ¯ask and cultured under standard
conditions (i.e. with loose caps at 37°C and 5% CO2). After
24 h the ¯asks were tightly closed and placed at various
temperatures (16, 21, 25, 30 and 37°C). Incubations at these
temperatures ranged from 16 to 36 h. For recovery after
the temperature treatment, the ¯asks were returned to the
incubator at 37°C with 5% CO2 with loosened caps for periods
ranging from 16 to 24 h.
RNA analysis
RNA was isolated from cells with TRI-Reagent (MRC,
Cincinnati, OH). HeLa cells were lysed in ¯asks, whereas
K562 cells were collected by centrifugation prior to TRI-
Reagent treatment. Approximately 200 ng of RNA was
analyzed by RT±PCR using rTth DNA polymerase as
suggested by the manufacturer (Perkin-Elmer). The
RT±PCR was carried out with [a-32P]dATP for 18 cycles
and the PCR products were separated on 7.5% non-denaturing
polyacrylamide gels. Under these conditions the amount of the
PCR product was proportional to the amount of input RNA, as
were the relative amounts of PCR products generated from
aberrantly and correctly spliced RNA (23,27,33). For analysis
of aberrantly and correctly spliced products, forward and
reverse primers spanning, respectively, positions 21±43 of
exon 2 (primer a) and positions 6±28 of exon 3 (primer b) of
the human b-globin gene were used. For RT±PCR analysis of
the expression of b-globin pre-mRNAs in HeLa and K562
cells, primer a was used in combination with primer c,
spanning positions 119±143 of b-globin intron 2 (Fig. 1) (23).
Protein analysis
The preparation of total protein and immunoblot analysis with
polyclonal af®nity-puri®ed chicken anti-human hemoglobin
antibody was described previously (19,23). The blots were
developed with the ECL detection system (Amersham). All
autoradiograms were captured by a DAGE-MTI (Michigan
City, IN) CCD72 video camera and computer prints of ®nal
®gures were generated. For EGFP detection, ¯uorescent
images of HeLa cells were taken with an Olympus inverted
¯uorescence microscope as described in Sazani et al. (32).
RESULTS
Temperature-dependent shift in splicing of IVS2-705
pre-mRNA
The IVS2-705 HeLa cell line stably expresses the mutated
b-globin gene in which a T®G mutation at nucleotide 705 of
intron 2 activated an aberrant 5¢ splice site in the b-globin pre-
mRNA (GAU/GUAAGA®GAG/GUAAGA). Due to the
IVS2-705 mutation and activation of the 3¢ splice site
upstream, the cells produce an aberrantly spliced b-globin
mRNA that retains a 126 nt portion of the intron (Fig. 1). As
shown previously (19,23), under normal growth conditions
(37°C) the only detectable b-globin mRNA was aberrantly
spliced; RT±PCR with primers ¯anking intron 2 (primers a
and b, Fig. 1) resulted in only one product (357 nt; Fig. 2A,
lane 5). However, in cells grown at 21 and 25°C, an additional
correctly spliced b-globin mRNA was generated (231 nt;
Fig. 2A, lanes 2 and 3, respectively). The amounts of correct
b-globin mRNA were negligible both at lower (16°C) and
higher (30°C) temperatures (Fig. 2A, lanes 1 and 4, respect-
ively). The shift in splicing from aberrant to correct was time
dependent; at 21°C the amount of correctly spliced b-globin
mRNA increased progressively between 16 and 36 h of
incubation (Fig. 2B, lanes 1±3). Within this period the cell
count remained constant (data not shown), indicating that the
Figure 1. Splicing of human b-globin IVS-2 mutant pre-mRNAs. Boxes,
exons; solid heavy lines, introns; thin solid and dotted lines above intron 2,
correct and aberrant splicing pathways, respectively; arrows, primers used
in RT±PCR detecting spliced (a and b) and unspliced (a and c) b-globin
RNAs. The aberrant 5¢ splice sites (654, 705 and 745) and the 3¢ cryptic
splice sites (3¢cr) are indicated; their sequences are shown below the scheme
(mutated nucleotides in bold).
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cells slowed, if not stopped, their growth and progression
through the cell cycle.
Figure 3 indicates that reduction of the cellular growth rate
at 21°C did not prevent translation of newly generated correct
b-globin mRNA. Immunoblot analysis with an anti-human
hemoglobin antibody showed that the level of b-globin protein
present in the cells increased over background (Fig. 3, lane 1)
during prolonged incubation at low temperature, consistent
with the shift in splicing from aberrant to correct (Fig. 3, lanes
2±4). This result shows that the low temperature is not lethal to
the cells and that the translational machinery of the cell is
functioning apparently unaffected by the low temperature
treatment (see also below). Importantly, increased translation
of b-globin peptide con®rms that the appearance of correct
b-globin mRNA is a consequence of its de novo synthesis and
therefore must be due to a shift in splicing. Note also that the
cell quiescence and the shift in the splicing pattern were
reversed when the cells were returned from 21 to 37°C (data
not shown). These results indicated that after incubation at
21°C the IVS2-705 HeLa cells remained viable and that the
splicing machinery shifted to its pattern of recognition of
aberrant slice sites.
Expression of IVS2-705 pre-mRNA at low temperature
It was not clear why the increased production of correct
b-globin mRNA at 30, 25 and 21°C was not maintained at
16°C. To address this question we re-assayed the RNAs
obtained in the experiments described in the previous section
using a pair of RT±PCR primers that detected only the
b-globin pre-mRNA (primers a and c; Fig. 1). Figure 4A
shows that signi®cant levels of IVS2-705 pre-mRNA accu-
mulated in the cells grown at 16, 21 and 25°C (lanes 1±3), but
not at 30 and 37°C (lanes 4 and 5). Furthermore, incubation of
the cells at 21°C for 16±36 h (Fig. 4B, lanes 1±3) generated
increasing amounts of IVS2-705 pre-mRNA within this
period, whereas in the control culture at 37°C, pre-mRNA
was barely detectable (Fig. 4B, lane 4). Although it cannot be
formally excluded that the decrease in temperature from 37 to
21°C activated the synthesis of pre-mRNA, thereby increasing
its intracellular concentration, a more likely explanation is that
at lower temperatures the rate of processing of the newly
transcribed pre-mRNA was slowed down more than the rate of
transcription. It appears then that at 25 and 21°C splicing was
slowed down and, in addition, shifted from aberrant to correct,
while at 16°C it was completely arrested, resulting in lack of
correct b-globin mRNA.
Splicing of IVS2-654, IVS2-745 and IVS2-705con
pre-mRNAs at low temperature
Temperature-dependant splicing was tested in HeLa cells that
expressed the IVS2-654 thalassemic mutant of the b-globin
gene. In IVS2-654 pre-mRNA the aberrant splice site is
created by a C®U mutation at nucleotide 654 of b-globin
intron 2 (AAG/GCAAUA®AAG/GUAAUA). Aberrantly
spliced IVS2-654 mRNA retains a 73 nt fragment of the
intron. This mutation was previously characterized as less
susceptible to correction of splicing by an antisense oligo-
nucleotide than IVS2-705 (23) and therefore it seemed
possible that it might be less susceptible to changes in
temperature. Indeed, treatment of IVS2-654 HeLa cells for 24
h at temperatures ranging from 16 to 37°C did not result in a
Figure 2. Temperature-dependent alteration of splicing of b-globin pre-
mRNA in IVS2-705 HeLa cells. Analysis of total RNA by RT±PCR with
primers a and b shown in Figure 1. (A) Temperature effects. Lanes 1±4,
cells incubated for 24 h at increasing temperatures (indicated at the top);
lane 5, control cells incubated at 37°C. The sizes (in nucleotides) of PCR
bands representing aberrantly and correctly spliced mRNAs are indicated on
the left. (B) Time course. Lanes 1±3, cells incubated at 21°C for the times
indicated at the top; lane 4, control cells incubated at 37°C; lane 5, RNA
from human blood (Hb). Unless otherwise indicated, similar designations
were used in subsequent ®gures.
Figure 3. Restoration of b-globin protein translation in IVS2-705 HeLa
cells. Immunoblot of total protein with anti-human hemoglobin antibody
(see Materials and Methods). Lane 1, control cells incubated at 37°C;
lanes 2±4, cells incubated at 21°C for 16, 24 and 36 h, respectively; lane 5,
human b-globin polypeptide.
Figure 4. Temperature-dependent alteration of expression of b-globin pre-
mRNA in IVS2-705 HeLa cells. (A) Temperature effects. Lanes 1±5, cells
incubated for 24 h at temperatures indicated at the top. (B) Time course.
Lanes 1±3, cells incubated at 21°C for the times indicated; lane 4, control
cells maintained at 37°C; lane 5, size marker; DNA from a plasmid carrying
the human b-globin gene subjected to PCR. RT±PCR and PCR were carried
out with primers a and c (Fig. 1).
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shift from aberrant to correct splicing at any temperature
(Fig. 5A).
The IVS2-745 mutation leads to aberrantly spliced b-globin
mRNA that retains a 165 nt long intron fragment. The IVS2-
745 5¢ splice site (CAG/GUACCA) is more distant from the
consensus than its 654 and 705 counterparts, resulting in
partially correct splicing in the HeLa cell line (see Fig. 5B,
lane 1) that was very susceptible to antisense oligonucleotide
treatment (23). Accordingly, treatment of IVS2-745 HeLa
cells at 21°C led to disappearance of the aberrant mRNA after
only 1 h treatment (Fig. 5B, lane 2). The transcribed pre-
mRNA continued to be spliced correctly in a time-dependent
manner, as evidenced by the increase in the intensity of the
correctly spliced RT±PCR product after 5 and 24 h at room
temperature (Fig. 5B, lanes 3 and 4).
Since the IVS2-654, IVS2-705 and IVS2-745 RNAs differ
not only in the sequences of the aberrant 5¢ splice sites (AAG/
GUAAUA, GAG/GUAAGA and CAG/GUACCA, respect-
ively) but also in the length (73, 126 and 165 nt) and hence the
sequence of the retained intron fragment, we have tested
another cell line expressing IVS-705con b-globin pre-mRNA.
In the IVS2-705con construct, a GAG/GUAAGA®GAG/
GUAAGU mutation increased the match of the aberrant 5¢
splice site to the consensus splice site sequence. Note that this
mutation does not alter the position of the aberrant 5¢ splice
site and therefore the product of aberrant splicing of IVS2-
705con pre-mRNA also retains 126 nt of the intron. Thus,
splicing of IVS2-705 and IVS2-705con results in identical
aberrant and correct b-globin mRNAs.
In contrast to IVS2-705 cells, correct splicing of b-globin
mRNA was not induced in IVS2-705con cells either by 24 h
incubation at low temperatures (Fig. 6A, lanes 1±4) or by
prolonged incubation at 21°C (Fig. 6B, lanes 1±3). Note also
that the four ~1600 nt long pre-mRNAs are identical except
for single point mutations at the aberrant 5¢ splice sites,
making it unlikely that the pre-mRNAs, the actual substrates
for the splicing reaction, differed signi®cantly in their
secondary and/or tertiary structures. Thus it appears that
temperature-dependent changes in the ratio of aberrant to
correct b-globin mRNAs are due to alteration of the splicing
process itself and not to temperature effects unrelated to
splicing, such as variations in stability of different mRNAs.
Temperature-dependent shift in splicing of IVS2-705
pre-mRNA in K562 cells
To ascertain that the observed change in splicing of b-globin
RNA is not a peculiarity of HeLa cells, we have subjected a
different cell line, K562 IVS2-705, to analogous temperature
treatments. K562 cells are of particular interest since they are
of human erythroid origin and can be induced to express the a-
and g-globin genes (34). It is conceivable that these cells may
have developed a specialized globin-related splicing machin-
ery that differs from that of HeLa cells. In fact, comparison of
splicing patterns in IVS2-705 HeLa and K562 cells (Fig. 2A,
lane 5 versus Fig. 7A, lane 5) shows a detectable level of
correct b-globin mRNA in the latter but not the former cell
line. However, in spite of this difference, IVS2-705 K562 cells
exhibited a temperature- and time-dependent shift in b-globin
splicing (Fig. 7A and B) similar to that seen in HeLa cells.
Thus, the temperature sensitivity of the IVS2-705 splicing
mutation exists in at least two different cellular backgrounds.
Temperature-dependent shift in splicing of the
IVS2-705con EGFP analog
A recently developed cellular assay for shifting splicing is
based on constructs in which the thalassemic b-globin introns
(IVS2-654 and IVS2-705) were inserted into the coding
sequence for EGFP (Fig. 8A) (32). Similarly to mutated b-
globin pre-mRNA, these mutations prevent proper splicing
and translation of EGFP, and dose-dependent increases in
EGFP production in response to treatment with antisense
oligonucleotides that block the aberrant splicing pathway were
seen (32). Insertion of IVS2-654 into the EGFP coding
sequence yielded a construct that exhibited no correct splicing,
as was expected from studies with IVS2-654 in b-globin.
However, splicing of IVS2-705 yielded a signi®cant amount
of background correct splicing (S.H.Kang and R.Kole,
unpublished results). The latter result is most likely due to
that fact that the correct 5¢ splice site at the end of the inserted
Figure 5. Aberrant splicing of IVS2-654 pre-mRNA is resistant to tempera-
ture change. (A) IVS2-654 HeLa cells were incubated for 24 h at the
temperatures indicated at the top (lanes 1±5). Lane 6, RNA from human
blood. (B) IVS2-745 HeLa cells were incubated for the indicated times at
21°C (lanes 1±4). Lane 5, RNA from human blood.
Figure 6. Temperature-dependent alteration of splicing of b-globin
pre-mRNA in IVS2-705con HeLa cells. All designations in (A) and (B) are
as in the legend to Figure 2.
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intron is closer to the consensus in the EGFP construct than in
b-globin (GAG/GTGAGT and AGG/GTACAG, respectively)
(35). When the spliced in IVS2-705 insert was strengthened to
the consensus (IVS2-705con, GAG/GTAAGT) the resulting
construct showed no background EGFP expression (Fig. 8B)
and was sensitive to correction of splicing by antisense
oligonucleotides (P.Sazani and R.Kole, unpublished results).
Figure 8B shows the results of incubation of HeLa EGFP-
705con cells at 21°C for 24 h followed by subsequent analysis
by ¯uorescence microscopy. While untreated cells did not
exhibit any detectable ¯uorescence, the majority of cells
subjected to low temperature were strongly ¯uorescent,
indicating signi®cant production of EGFP. Interestingly,
HeLa EGFP-654 cells exposed to decreased temperature
also displayed correction of splicing, re¯ected in production of
EGFP protein. Clearly, temperature-dependent shifts in spli-
cing take place not only in b-globin pre-mRNA but also when
the b-globin intron is ¯anked by foreign, non-globin
sequences. Moreover, the susceptibility of both EGFP-
705con and EGFP-654 to lower temperature indicates that
the outcome is in¯uenced by the ¯anking splice sites and
possibly sequences of the ¯anking exons. As in the b-globin
experiments, de novo synthesis of EGFP protein indicates that
the temperature effects were due to newly spliced EGFP
mRNA and not because of a change in stability of pre-existing
transcripts.
DISCUSSION
It is clear that there is no single determining sequence element
responsible for splice site selection. Rather, splicing of a pre-
mRNA is the end result of the effects of many parameters on
the formation of the spliceosome. The current data indicate
that for splicing of the IVS2-654, IVS2-705 and IVS2-745
mutations, temperature can affect the interplay between the
aberrant splice sites and other splicing elements and their
interactions with splicing factors. For example, both the IVS2-
654 and IVS2-705con introns in their native b-globin gene
were unresponsive to decreased temperature, but when
inserted into the EGFP coding sequence, which provided
stronger ¯anking splice sites, the aberrant exon within the
introns was skipped in a temperature-dependent fashion. Thus,
the stronger correct 5¢ splice site in the EGFP construct
diminished but did not eliminate recognition of the aberrant
splice sites by the spliceosome. Likewise, lower temperature
may have decreased the utility of an enhancer element in the
aberrant exon, the existence of which has been strongly
suggested by mutational analysis of that region (36). The
enhancer element, in turn, was likely in¯uenced by the
sequence and the length of the internal aberrant exons in the
different IVS2 mutants.
The above conclusions are also supported by our previous
®ndings of varying susceptibility of the thalassemic b-globin
pre-mRNAs to treatment with antisense oligonucleotides (23).
Treatment of HeLa cells expressing IVS2-654, IVS2-705 and
IVS2-745 thalassemic b-globin genes with antisense oligo-
nucleotides targeted to the common aberrant 3¢ splice site
resulted in correction of splicing in all three cases, but the
effective concentrations of the oligonucleotides required for
50% correction (EC50) were 1560, 31 and 2 nM, respectively
(i.e. up to a 700-fold difference). These data agree with the
results of the present work, since aberrant splicing of IVS2-
705 and IVS2-745 pre-mRNAs was prevented by both the
temperature shift and the oligonucleotides, while both treat-
ments were relatively ineffective for IVS2-654 pre-mRNA.
Similarly, the resistance of IVS2-705con to changes induced
by low temperature is in agreement with its increased
resistance to correction by the antisense oligonucleotides
(23). Thus, it appears that both treatments interfere with
proper assembly of the spliceosomes at the aberrant splice
sites of IVS2-705 and IVS2-745, but not IVS2-654 and IVS2-
705con, pre-mRNAs.
Figure 8. Temperature-dependent alteration of splicing of EGFP-654 and
705con in HeLa cells. (A) Splicing of EGFP IVS-2 mutant pre-mRNAs.
Designations are as in Figure 1. (B) Bright ®eld (left) and ¯uorescence
images (right) of cells treated at the indicated temperature.
Figure 7. Temperature-dependent alteration of splicing of b-globin
pre-mRNA in IVS2-705 K562 cells. All designations in (A) and (B) are as
indicated in the legend to Figure 2.
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Interestingly, low temperature cell culture may also bring
about inclusion rather than skipping of an exon. For example,
several different mutations in the 5¢ splice sites of the human
collagen genes, which are responsible for the genetic disorders
termed Ehlers±Danlos and osteogenesis imperfecta syn-
dromes, led to exon skipping in patient's ®broblasts cultured
at 37°C. However, the rates of exon skipping markedly
decreased when the cells were incubated at 31°C (37±40).
Similarly, in the murine retrovirus MuSVts110, the splicing of
viral RNA was reduced at 37°C and increased at 33°C (41),
while exon skipping was prevented in a mutant ¯oral homeotic
gene AP3 of Arabidopsis thaliana when cell culture tempera-
ture was shifted from 28 to 16°C (42). It was concluded in
these reports that exon inclusion at low temperature was due to
improved hybridization of U1 snRNA to the mutated 5¢ splice
sites (37±40) while improved splicing of MuSVts110 retro-
virus appeared to be due to enhanced hybridization of U2 to a
weak branch point (41). The fact that in the b-globin pre-
mRNAs the lower temperature decreased rather than increased
inclusion of the aberrant exon indicated that different mech-
anisms must have operated during splicing of those RNAs.
The ®ndings of the present study also suggest the intriguing
possibility of lowering the temperature of bone marrow,
perhaps in the extremities, as a treatment for b-thalassemia
arising from the IVS2-705 or IVS2-745 mutations (18).
Hypothermic treatments have been successfully used to
reduce deleterious consequences of cardiac arrest (43).
Splicing of various mRNAs is affected in a different manner
not only by a decrease but also by an increase in the
temperature of cell culture. In our hands, a 3 h 42°C heat shock
of IVS2-654 and IVS2-705 HeLa cells had no effect on
aberrant splicing of the two thalassemic b-globin mRNAs
(data not shown). However, activation of a 5¢ splice site and a
novel alternatively spliced murine HSP47 mRNA was
detected in 3T3 cells subjected to heat shock at 42°C (44).
A mutation in the 5¢ splice site of intron 37 of type III
procollagen, in contrast to the collagen mutations discussed
above, led to a minor, but statistically signi®cant, decrease in
exon skipping when the temperature of the cell culture was
raised from 31 to 37°C (45). These results reinforce our
conclusion that variations in temperature affect the spliceo-
some and/or its interactions with speci®c splice sites and other
sequence elements involved in splicing.
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